A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852) Journal Article


Authors: Thaker, P. H.; Salani, R.; Brady, W. E.; Lankes, H. A.; Cohn, D. E.; Mutch, D. G.; Mannel, R. S.; Bell-McGuinn, K. M.; Di Silvestro, P. A.; Jelovac, D.; Carter, J. S.; Duan, W.; Resnick, K. E.; Dizon, D. S.; Aghajanian, C.; Fracasso, P. M.
Article Title: A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852)
Abstract: Background: Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects of cisplatin. Given the use of cisplatin and paclitaxel as first-line treatment for persistent or recurrent cervical cancer, we aimed to estimate the maximum tolerated dose (MTD) of the PARP inhibitor veliparib when added to chemotherapy. Patients and methods: Women with persistent or recurrent cervical carcinoma not amenable to curative therapy were enrolled. Patients had to have received concurrent chemotherapy and radiation as well as possible consolidation chemotherapy; have adequate organ function. The trial utilized a standard 3+3 phase I dose escalation with patients receiving paclitaxel 175mg/m2 on day 1, cisplatin 50mg/m2 on day 2, and escalating doses of veliparib ranging from 50 to 400mg orally two times daily on days 1-7. Cycles occurred every 21 days until progression. Dose-limiting toxicities (DLTs) were assessed at first cycle. Fanconi anemia complementation group D2 (FANCD2) foci was evaluated in tissue specimens as a biomarker of response. Results: Thirty-four patients received treatment. DLTs (n=1) were a grade 4 dyspnea, a grade 3 neutropenia lasting‚Č•3 weeks, and febrile neutropenia. At 400mg dose level (DL), one of the six patients had a DLT, so the MTD was not reached. Across DLs, the objective response rate (RR) for 29 patients with measurable disease was 34% [95% confidence interval (CI), 20%-53%]; at 400mg DL, the RR was 60% (n=3/5; 95% CI, 23%-88%). Median progression-free survival was 6.2 months (95% CI, 2.9-10.1), and overall survival was 14.5 months (95% CI, 8.2-19.4). FANCD2 foci was negative or heterogeneous in 31% of patients and present in 69%. Objective RR were not associated with FANCD2 foci (P=0.53). Conclusions: Combining veliparib with paclitaxel and cisplatin as first-line treatment for persistent or recurrent cervical cancer patients is safe and feasible. ¬© The Author 2016.
Keywords: cervical cancer; novel therapeutics; parp inhibitors
Journal Title: Annals of Oncology
Volume: 28
Issue: 3
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2017-03-01
Start Page: 505
End Page: 511
Language: English
DOI: 10.1093/annonc/mdw635
PROVIDER: scopus
PUBMED: 27998970
PMCID: PMC5815561
DOI/URL:
Notes: Article -- Export Date: 2 June 2017 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors